MTREX

Across TCGA pan-cancer cohorts, MTREX RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of MTREX’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where MTREX RNA is repressed in tumor relative to normal tissue. In most cancer types MTREX is over-expressed in tumor, although a few such as THCA and UCEC show the opposite, repressed pattern.

THCA, LIHC, and COAD are the cancer types where MTREX tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MTREX RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−0.491	<.001	9	view →
LIHC	All	II,III,IV	+0.837	<.001	8	view →
COAD	Male	All	+0.427	<.001	5	view →
STAD	All	II,III,IV	+0.420	.007	5	view →
LUAD	Male	All	+0.493	<.001	4	view →
CHOL	All	All	+1.563	<.001	3	view →
READ	All	III,IV	+0.855	.012	2	view →
UCEC	All	All	−0.502	.018	2	view →
KICH	All	All	−0.489	.029	2	view →
KIRC	All	All	+0.202	.016	2	view →
KIRP	Male	All	−0.287	.047	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

MTREX–THCA

Open the THCA breakdown →